Treatment of Chronic Idiopathic Systemic Vasculitides

  • Gary S. Hoffman
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 336)


The following review is intended to summarize currently accepted, as well as newly appreciated therapies for the chronic systemic vasculitides. In recent years, a great deal has been learned about enhancement and inhibition of immunoinflammatory phenomena. Biological, immunomodulatory agents with focussed actions are just beginning to be tested in the clinical setting. However, until these promising approaches have been more thoroughly evaluated, it will continue to be necessary to cautiously titrate broadly immunosuppressive medications for the treatment of these disorders.


Kawasaki Disease Giant Cell Arteritis Systemic Vasculitis Polyarteritis Nodosa High Dose Intravenous Immunoglobulin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    G.S. Hoffman and G.S. Kerr, Recognition of systemic vasculitis in the acutely ill patient, In: “Management of Critically Ill Patients with Rheumatologic and Immunologic Diseases,” B.F. Mandell, ed., Marcel Dekker, Inc. (1993).Google Scholar
  2. 2.
    P.P. Frohnert and S.G. Sheps, Longterm follow-up study of polyarteritis nodosa, AmJMed. 43: 8–14 (1967).Google Scholar
  3. 3.
    E.S. Leib, C. Restivo, and H.E. Paulus, Immunosuppressive and corticosteroid therapy of polyarteritis nodosa, Am JMed 67: 941 (1979).Google Scholar
  4. 4.
    R.D. Cohen, D.L. Conn, and D.M. Ilstrup, Clinical features, prognosis and response to treatment in polyarteritis, Mayo Clin Proc. 55: 146 (1980).PubMedGoogle Scholar
  5. 5.
    L. Guillevin, L.T.H. Du, P. Godeau, P. Jais, and B. Wechsler, Clinical findings and prognosis of polyarteritis nodosa and Churg-Strauss angiitis: a study of 165 patients, Brit J Rheumatol 27: 258 (1988).CrossRefGoogle Scholar
  6. 6.
    L. Guillevin, and The Cooperative Study Group for the study of polyarteritis nodosa: Treatment of polyarteritis nodosa and Churg-Strauss angiitis: indication of plasma exchange results of three prospective trials in 162 patients, Apheresis. 337: 309 (1990).Google Scholar
  7. 7.
    L. Guillevin, B. Jarrousse, C. Lok, F. Lhote, J.P. Jais, L.T.H. Du, A. Busse], et al., Longterm followup after treatment of polyarteritis nodosa and Churg-Strauss angiitis with comparison of steroids, plasma exchange, and cyclophosphamide to steroids and plasma exchange, A prospective randomized trial of 71 patients, JRheumatol. 18: 567 (1991).Google Scholar
  8. 8.
    R.A. Lugmani, M. Gordon, I. Greaves, D. Adu, J. Michael, P. Emery, and P.A. Bacon, Necrotizing vasculitis-relapse despite cytotoxic therapy, Arthritis Rheum. 34: S51 (1991).Google Scholar
  9. 9.
    C. Trepo, D. Ouzan, J. Delmont, and J. Tremisi, Supé riorité d’une nouveau traitement étiopathogé nique curateur des périartérities noueuses induites par le virus de d’hé patite B grâce à l’association corticothérapie brève, vidarabine, échanges plasmatiques, La Presse Méd. 30: 1527 (1988).Google Scholar
  10. 10.
    L. Guillevin, Y. Merrouche, M. Gayraud, B. Jarrousse, I. Royer, A. Léon, and J. Baudelot, Périarterite noueuse lié e au virus de hépatite B. Détermination d’une stratégie therapeutique nouvelle: 13 observations, La Press Méd. 17: 1522 (1988).Google Scholar
  11. 11.
    C.W. Carson, D.L. Conn, A.J. Czaja, and M.E. Brecher, Frequency and significance of antibodies to hepatitis C virus in polyarteritis nodosa, Arthritis Rheum. 34: 891 (1991).Google Scholar
  12. 12.
    R.D. Inman, M. Hodge, M.E.A. Johnston, J. Wright, and J. Heathcote, Arthritis, vasculitis and cryoglobulinemia associated with relapsing hepatitis A infection, Ann Intern Med. 105: 700 (1986).PubMedCrossRefGoogle Scholar
  13. 13.
    A. Banji and R. Salisbury, Cytomegalovirus and vasculitis, Brit Med J. 1: 623 (1978).CrossRefGoogle Scholar
  14. 14.
    Z.D. Goodman, J.K. Boitrott, and J.H. Yardley, Perforation of the colon associated with cytomegalovirus infection, Digest Dis Sei. 24: 376 (1979).CrossRefGoogle Scholar
  15. 15.
    M. Doherty and J.W.B. Bradfield, Polyarteritis nodosa associated with acute cytomegalovirus infection, Ann Rheum Dis. 40: 419 (1981).PubMedCrossRefGoogle Scholar
  16. 16.
    P.R. Phinney, S. Fligiel, Y.J. Bryson, and D.D. Porter, Necrotizing vasculitis in a case of disseminated neonatal herpes simplex infection, Arch Pathol Lab Med. 106: 64 (1982).PubMedGoogle Scholar
  17. 17.
    G.S. Hoffman and W.A. Franck, Infectious mononucleosis, autoimmunity and vasculitis, JAMA. 241: 2735 (1979).PubMedCrossRefGoogle Scholar
  18. 18.
    L.H. Calabrese, M. Estes, B. Yen-Lieberman, M.R. Proffitt, R. Tubbs, A.J. Fishleder, and K.H. Levin, Systemic vasculitis in association with human immunodeficiency virus infection, Arthritis Rheum. 32: 569 (1989).PubMedCrossRefGoogle Scholar
  19. 19.
    E.W. Walton, Giant cell granuloma of the respiratory tract (Wegener’s granulomatosis), Brit Med J. 2: 265 (1958).PubMedCrossRefGoogle Scholar
  20. 20.
    G.S. Hoffman, G.S. Kerr, R.Y. Leavitt, C.W. Hallahan, R.S. Lebovics, W.D. Travis, M. Rottem, and A.S. Fauci, Wegener’s granulomatosis: an analysis of 158 patients, Ann Intern Med. 116: 488 (1992).PubMedCrossRefGoogle Scholar
  21. 21.
    A.S. Fauci and S.M. Wolff, Wegener’s granulomatosis: studies in eighteen patients and a review of the literature, Medicine. 52: 535 (1973).PubMedCrossRefGoogle Scholar
  22. 22.
    A.S. Fauci, B.F. Haynes, P. Katz, and S.M. Wolff, Wegener’s granulomatosis: Prospective clinical and therapeutic experience with 85 patients for 21 years, Ann Intern Med 98: 76 (1983).PubMedCrossRefGoogle Scholar
  23. 23.
    R.J. Falk, S. Hogan, J.C. Jennette, and The Glomerular Disease Collaborative Network, Clinical course of antineutrophil cytoplasmic antibody associated glomerulonephritis and systemic vasculitis, Ann Intern Med. 113: 656 (1990).PubMedCrossRefGoogle Scholar
  24. 24.
    G.S. Hoffman, R.Y. Leavitt, T.A. Fleisher, J.R. Minor, and A.S. Fauci, Treatment of Wegener’s granulomatosis with intermittent high-dose intravenous cyclophosphamide, Am JMed. 89: 403 (1990).Google Scholar
  25. 25.
    D. Steppat and W.L. Gross, Stage adapted treatment of Wegener’s granulomatosis, Klin Wochenschr. 67: 666 (1989).PubMedCrossRefGoogle Scholar
  26. 26.
    R.A. DeRemee, T.J. McDonald, and L.H. Weiland, Wegener’s granulomatosis: observations on treatment with antimicrobial agents, Mayo Clin Proc. 60: 27 (1985).PubMedCrossRefGoogle Scholar
  27. 27.
    H.L. Israel. Sulfamethoxazole-trimethoprim therapy for Wegener’s granulomatosis, Arch Intern Med. 148: 2293 (1988).PubMedCrossRefGoogle Scholar
  28. 27a.
    G.S. Hoffman, R.Y. Leavitt, G.S. Kerr, A.S. Fauci, The treatment of Wegener’s granulomatosis with glucocorticoids and methotrexate. Arthritis Rheum. 35: 1322 (1992).PubMedGoogle Scholar
  29. 28.
    D.R.W. Jayne, M.J. Davies, C.J.V. Fox, C.M. Black, and C.M. Lockwood, Treatment of systemic vasculitis with pooled intravenous immunoglobulin, Lancet. 337: 1137 (1991).PubMedCrossRefGoogle Scholar
  30. 29.
    J.H. Shelhamer, D.J. Volkman, J.E. Parillo, et al., Takayasu’s arteritis and its therapy, Ann Intern Med. 103: 121 (1985).PubMedCrossRefGoogle Scholar
  31. 30.
    G.S. Hoffman, R.Y. Leavitt, G.S. Kerr, M. Rottem, and A.S. Fauci, Treatment of Takayasu’s arteritis with methotrexate, Arthritis Rheum. 34: 874 (1991).CrossRefGoogle Scholar
  32. 31.
    P. Lagneau, J.B. Michel, and P.N. Vuong, Surgical treatment of Takayasu’s disease, Ann Surg. 205: 157 (1987).PubMedCrossRefGoogle Scholar
  33. 32.
    E. Kieffer, A. Piquois, A. Bertal, O. Beetry, and P. Godeau, Reconstructive surgery of the renal arteries in Takayasu’s disease, Ann VaseSurg. 4: 156 (1990).Google Scholar
  34. 33.
    J.M. Giordano, R.Y. Leavitt, G.S. Hoffman, and A.S. Fauci, Experience with surgical treatment of Takayasu’s disease, Surgery. 109: 252 (1991).PubMedGoogle Scholar
  35. 34.
    K. Ishikawa. Natural history and classification of occlusive thromboaortopathy (Takayasu’s disease), Circulation. 57: 27 (1978).PubMedCrossRefGoogle Scholar
  36. 35.
    K. Ishakawa, Survival and morbidity after diagnosis of occlusive thromboaortopathy (Takayasu’s disease), Am J Cardiology. 47: 1026 (1981).CrossRefGoogle Scholar
  37. 36.
    J.M. Dwyer, Manipulating the immune system with immune globulin, NEngIJMed. 326: 107 (1992).Google Scholar
  38. 37.
    J.W. Newburger, M. Takahashi, J.C. Burns, A.S. Beiser, K.J. Chung, E. Duffy, M.P. Glade, et al., The treatment of Kawasaki syndrome with intravenous gamma globulin, NEngl JMed. 315: 341 (1986).CrossRefGoogle Scholar
  39. 38.
    J.W. Newberger, M. Takahashi, A.S. Beiser, J.C. Burns, J. Bastian, K.J. Chung, et al., A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome, NEngIJMed. 324: 1633 (1991).CrossRefGoogle Scholar
  40. 39.
    K. Furusho, H. Nakano, K. Shinomiya, T. Tamura, Y. Manabe, M. Karvarano, K. Baba, et al., High-dose intravenous gamma globulin for Kawasaki Disease, Lancet. 2: 1055 (1984).PubMedCrossRefGoogle Scholar
  41. 40.
    H. Becker, G. Mitropoulou, and K. Helmke, Immunomodulating therapy in rheumatoid arthritis by high dose intravenous immunoglobulin, Klin Wochenschr. 67: 286 (1989).PubMedCrossRefGoogle Scholar
  42. 41.
    P. Cheringelfand, S. Herson, B. Wechsler, J.-C. Piette, O. Bletry, A. Coutellier, J.-M. Ziza, Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients, Am JMed. 91: 162 (1991).Google Scholar
  43. 42.
    E.W. Gelfand, The use of intravenous immune globulin in collagen vascular disorders: A potentially new modality of therapy, JAllergy Clin Immunol 84: 613, (1989).CrossRefGoogle Scholar
  44. 43.
    B.A. Lang, R.M. Laxer, G. Murphy, E.D. Silverman, and C. Roifman, Treatment of dermatomyositis with intravenous gammaglobulin, Am JMed 91: 169 (1991).Google Scholar
  45. 44.
    G.E. Grau, P. Roux-Lombard, C. Gysler, C. Lambert, P.H. Lambert, J.M. Dayer, L. Guillevin, Serum cytokine changes in systemic vasculitis, Immunology. 68: 196 (1989).PubMedGoogle Scholar
  46. 45.
    Y. Deguchi, N. Shibata, and S. Kishimoto, Enhanced expression of the tumour necrosis factor/cachectic gene in peripheral blood mononuclear cells from patients with systemic vasculitis, Clin Exp Immunol. 81: 311 (1990).PubMedCrossRefGoogle Scholar
  47. 46.
    D. Wofsy and W.E. Seaman, Reversal of advanced immune lupus in NZB/NZW Fl mice by treatment with monoclonal antibody to L3T4, Jlmmunol 138: 3247 (1987).Google Scholar
  48. 47.
    P.W. Mathieson, S.P. Cobbold, G. Hale, M.R. Clark, D.B.G. Oliveira, C.M. Lockwood, and H. Waldmann, Monoclonal-antibody therapy in systemic vasculitis, NEngl JMed. 323: 250 (1990).CrossRefGoogle Scholar
  49. 48.
    C. Herzog, C. Wallur, W. Pichler, A. Aeschlimann, et al., Monoclonal anti-CD4 in arthritis, Lancet. 2: 1461 (1987).PubMedCrossRefGoogle Scholar
  50. 49.
    K.J. Tracey, Y. Fong, D.G. Hesse, K.R. Manogue, A.T. Lee, G.C. Kuo, S.F. Lowry, and A. Ceramie, Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia, Nature. 330: 662 (1987).PubMedCrossRefGoogle Scholar
  51. 50.
    R.D. Mayforth and J. Quintans, Designer and catalytic antibodies, NEngl JMed. 323: 173 (1990).CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1993

Authors and Affiliations

  • Gary S. Hoffman
    • 1
  1. 1.Vasculitis and Related Diseases Section Laboratory of Immunoregulation National Institute of Allergy and Infectious DiseasesNational Institutes of HealthBethesdaUSA

Personalised recommendations